Back to discover
Disease
Acquired Immunodeficiency Syndrome
Late-stage therapeutic developmentEmerging researchRising momentum
3
Publications
24
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.
Research2023-04-24Frontiers in immunology
Reflections on 40 Years of AIDS.
Research2021-06-01Emerging infectious diseases
Diarrhea in developed and developing countries: magnitude, special settings, and etiologies.
Research1990-01-01Reviews of infectious diseases
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 1 clinical trial expected to report results, the earliest in Q3 2030.
Major developments
Major trial resultsHigh impact
Results posted2026-07-08
Upcoming trial readoutHigh impact
Results expected Q3 20302026-06-04
Clinical MilestonesViewHide
Results posted
- 2026-07-08A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically SuppressedResults posted
- 2026-03-19A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsResults posted
Results expected
Recently completed
- 2026-04-17A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)Primary completion
- 2025-10-13A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve ParticipantsPrimary completion
Other updates
- 2026-06-06Extracts of Plants Eclipta Prostrata, Dioscorea Cirrhosa, Phyllanthus Urinaria, Adenosma Glutinosum, Impatiens Balsamina and Ascorbic Acid Use for in Protecting and Increasing CD4+ T Lymphocytes; B Lymphocytes Level in HIV/AIDS Patients.Withdrawn
- 2026-03-16An Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Treatment-Naive People With HIV-1Terminated
- 2025-12-31A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected AdultsWithdrawn
Activity timeline8
- 2026-07-08ClinicalA Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically SuppressedResults posted
- 2026-06-06ClinicalExtracts of Plants Eclipta Prostrata, Dioscorea Cirrhosa, Phyllanthus Urinaria, Adenosma Glutinosum, Impatiens Balsamina and Ascorbic Acid Use for in Protecting and Increasing CD4+ T Lymphocytes; B Lymphocytes Level in HIV/AIDS Patients.Withdrawn
- 2026-06-04ClinicalA Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Results expected Q3 2030
- 2026-04-17ClinicalA Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)Primary completion
- 2026-03-19ClinicalA Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult ParticipantsResults posted
- 2026-03-16ClinicalAn Operationally Seamless Phase 2/3, Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Treatment-Naive People With HIV-1Terminated
- 2025-12-31ClinicalA Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected AdultsWithdrawn
- 2025-10-13ClinicalA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve ParticipantsPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
19902023
Most influential
Major themes8
- Acquired Immunodeficiency Syndrome2
- COVID-192
- Communicable Diseases1
- Disease Outbreaks1
- Hemorrhagic Fever, Ebola1
- HIV Infections1
- Malaria1
- Tuberculosis1
Leading journals3
- Emerging infectious diseases1
- Frontiers in immunology1
- Reviews of infectious diseases1
Leading researchers8
- Bettencourt PJG1
- Crane J1
- Curran JW1
- De Cock KM1
- Guerrant RL1
- Hughes JM1
- Jaffe HW1
- Lima NL1
Affiliations (unnormalised)2
- Center for Interdisciplinary Research in Health1
- University of Virginia School of Medicine1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.